Reipet – Lifestyle
Author:
Protagonist Therapeutics
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
April 28, 2026
Protagonist Therapeutics Reports Granting of Inducement Awards
April 16, 2026
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 30, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026